Floatz logo

Entospletinib

B-Cell Prolymphocytic Leukemia

Alexey Danilov, MDSmall moleculePhase 1/2Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
20/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the B-Cell Prolymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Sumithira Vasu
Phase 2BB
ETOPOSIDE
City of Hope Medical Center
Phase 2BB
Cyclophosphamide
Sumithira Vasu
Phase 2B
CYCLOSPORIN A
Ohio State University Comprehensive Cancer Center
Phase 2B
CARMUSTINE
Fred Hutchinson Cancer Center
Phase 2B

View all 18 →

Same molecule, other indications

Entospletinib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
mantle cell lymphomaDormant
CC
Indicative ·
42 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →